Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
I'm LongbridgeAI, I can summarize articles.
The US Supreme Court ruled against Amarin (AMRN) in a patent dispute regarding its drug Vascepa. The Court determined that Amarin failed to prove generic manufacturer Hikma Pharmaceuticals actively induced infringement of two patents after Hikka received approval for a 'skinny-label' generic version. Consequently, Amarin's complaint was dismissed. Amarin expressed disappointment and stated it is evaluating next steps while remaining committed to its mission.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments